<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="3" ids="27226">Uric acid</z:chebi> is a natural <z:chebi fb="11" ids="22586">antioxidant</z:chebi> that protects the brain in a model of transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in rats </plain></SENT>
<SENT sid="1" pm="."><plain>Here we sought to investigate whether <z:chebi fb="3" ids="27226">uric acid</z:chebi> was protective in a model of thromboembolic <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> in rats, and whether the global benefit of recombinant tissue plasminogen activator (rt-PA) was improved by the combined treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Adult male Sprague-Dawley rats underwent either <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> by thromboembolic middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) or sham operation </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="3" ids="27226">Uric acid</z:chebi> (16 mg/kg) was injected intravenously (i.v.) </plain></SENT>
<SENT sid="4" pm="."><plain>20 mins after MCAO, whereas rt-PA (10 mg/kg) was administered i.v. at 3 h </plain></SENT>
<SENT sid="5" pm="."><plain>A group of rats received the combined treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Rats underwent two neurologic examinations (30 mins and 24 h after MCAO) </plain></SENT>
<SENT sid="7" pm="."><plain>At 24 h, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was measured and brain neutrophil infiltration and protein tyrosine nitration were assessed </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment with either <z:chebi fb="3" ids="27226">uric acid</z:chebi> or rt-PA reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume versus controls (P&lt;0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>The protective effect against <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> was greater after cotreatment of <z:chebi fb="3" ids="27226">uric acid</z:chebi> with rt-PA (P&lt;0.001), which added further benefit to rt-PA alone (P&lt;0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>The neurologic score worsened during the first 24 h in treatment controls, whereas it improved in rats receiving <z:chebi fb="3" ids="27226">uric acid</z:chebi> and/or rt-PA </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="3" ids="27226">Uric acid</z:chebi> strongly reduced <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced tyrosine nitration, but it was more effective alone than combined with rt-PA, suggesting that reperfusion enhances nitrotyrosine formation </plain></SENT>
<SENT sid="12" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> treatments reduced postischemic brain neutrophil infiltration </plain></SENT>
<SENT sid="13" pm="."><plain>These results show that <z:chebi fb="3" ids="27226">uric acid</z:chebi> administered early after <z:hpo ids='HP_0001727'>thromboembolic stroke</z:hpo> is neuroprotective in the rat brain, as it reduces <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, ameliorates the neurologic function, attenuates the <z:mp ids='MP_0001845'>inflammatory response</z:mp>, and extends the benefits of rt-PA </plain></SENT>
</text></document>